DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 9.29 0.23%
S&P 500 1,864.85 2.54 0.14%
market minute promo

MannKind Corp


6.25 -0.14 (-2.19%)

REAL-TIME: Last trade at

Extended Hours: $6.25 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

MNKD $6.25 -2.19%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.34
Previous Close $6.39
Daily Range $6.22 - $6.46
52-Week Range $3.72 - $8.70
Market Cap $2.4B
P/E Ratio -9.98
Dividend (Yield) $0.00 (0.0%)
Volume 4,409,320
Average Daily Volume 14,522,823
Current FY EPS -$0.31





MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website:

News & Commentary

5 Questions for MannKind

The inhaled insulin drugmaker faces an FDA review in April, but when will AstraZeneca, Merck or one of the other major drugmakers step up and license Afrezza?

XBI, MNKD, UTHR, ARNA: Large Inflows Detected at ETF

MannKind (MNKD) Stock Continues Decline Today

The Stalled State Of MannKind

One Factor Driving MannKind (MNKD) Stock Down Today

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

Why I Believe MannKind Shares Will Rise Significantly Upon FDA Approval Of Afrezza

Company News for April 08, 2014 - Corporate Summary

UPDATE: Brinson Patrick Initiates Coverage on MannKind

MannKind Slips on Afrezza Approval Delay - Analyst Blog

MNKD July 19th Options Begin Trading

See More MNKD News...

MNKD's Top Competitors

MNKD $6.25 (-2.19%)
Current stock: MNKD
AMGN $115.46 (-0.07%)
Current stock: AMGN
GILD $70.00 (1.04%)
Current stock: GILD
BIIB $290.54 (-0.32%)
Current stock: BIIB